<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431274</url>
  </required_header>
  <id_info>
    <org_study_id>1237.5</org_study_id>
    <secondary_id>2009-010668-40</secondary_id>
    <nct_id>NCT01431274</nct_id>
  </id_info>
  <brief_title>Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The overall objective of this study is to assess the efficacy and safety of 52 weeks once
      daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT
      Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the
      RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 Response on Day 170.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 169</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 169</time_frame>
    <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response on Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment.</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response on Day 85</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85.</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response on Day 365</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365.</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 15.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 43</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43.</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 85</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 85.</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 169</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on Day 169</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 365</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 365</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment.</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 85</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85.</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 169</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 365</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365.</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 15.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 43.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 85.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 85</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 170.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 365.</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on Day 365.</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-12h) Response in the Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169.</time_frame>
    <description>FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-24h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169.</time_frame>
    <description>FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-12h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169.</time_frame>
    <description>FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-24h) Response in Sub-set of Patients With 24-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169.</time_frame>
    <description>FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 85</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 365</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 43</time_frame>
    <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 43 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 85</time_frame>
    <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 85 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</measure>
    <time_frame>Day 365</time_frame>
    <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 365 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2624</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>tiotropium+olodaterol low dose FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium+olodaterol high dose FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + olodaterol</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium+olodaterol low dose FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>low dose</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>one dose only</description>
    <arm_group_label>olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>high dose</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + olodaterol</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium+olodaterol high dose FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>Respimat inhaler</description>
    <arm_group_label>tiotropium+olodaterol low dose FDC</arm_group_label>
    <arm_group_label>tiotropium+olodaterol high dose FDC</arm_group_label>
    <arm_group_label>olodaterol</arm_group_label>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease.

          2. Relatively stable airway obstruction with post FEV1&lt; 80% predicted normal and post
             FEV1/FVC &lt;70%.

          3. Male or female patients, 40 years of age or older.

          4. Smoking history of more than 10 pack years.

        Exclusion criteria:

          1. Significant disease other than COPD

          2. Clinically relevant abnormal lab values.

          3. History of asthma.

          4. Diagnosis of thyrotoxicosis

          5. Diagnosis of paroxysmal tachycardia

          6. History of myocardial infarction within 1 year of screening visit

          7. Unstable or life-threatening cardiac arrhythmia.

          8. Hospitalization for heart failure within the past year.

          9. Known active tuberculosis.

         10. Malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. History of life-threatening pulmonary obstruction.

         12. History of cystic fibrosis.

         13. Clinically evident bronchiectasis.

         14. History of significant alcohol or drug abuse.

         15. Thoracotomy with pulmonary resection

         16. Oral ß-adrenergics.

         17. Oral corticosteroid medication at unstable doses

         18. Regular use of daytime oxygen therapy for more than one hour per day

         19. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         20. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA

         22. Pregnant or nursing women.

         23. Women of childbearing potential not using a highly effective method of birth control

         24. Patients who are unable to comply with pulmonary medication restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.5.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuidad Autonoma de Buenos Airess A</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monte Grande</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel de Tucuma</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shumen</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Troyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.02006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Foshan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nan Ning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beroun</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cvikov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 6</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rokycany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sønderborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bethune Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Pierre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neu-Isenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oschersleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.50207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kapuvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Törökbalint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montescano (PV)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aoba-ku, Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahikawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hakata-ku, Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamamatsushi, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ikoma, Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inashiki-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jonan-ku, Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagoshima, Kagoshima,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamogawa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyusyu,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koga, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komaki, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komaki, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshi, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>koto-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuki, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kure, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsusaka, Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minami-ku. Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Urasoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Urasoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sayama, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seto, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinagawa, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wakayama, Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yanagawa-shi, Fukuoka,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.81028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hermosillo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenlane East Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.35107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viseu</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gatchina (Leningradskaya oblast)</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.38601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.38602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmit</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.5.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>June 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <disposition_first_submitted>March 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2014</disposition_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This trial was one of 2 confirmatory Phase III 52-week, multi-centre, multi-national, randomised,double-blind, parallel group studies to evaluate the long-term efficacy and safety of once daily treatment with orally inhaled Tio+Olo FDC (2.5/5μg; 5/5μg) compared with the individual components (2.5μg; 5μg Tiotropium, 5μg Olodaterol) in COPD patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olodaterol (5 μg)</title>
          <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium (2.5 μg)</title>
          <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium (5 μg)</title>
          <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P4">
          <title>Tio+Olo FDC (2.5/5 μg)</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P5">
          <title>Tio+Olo FDC (5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="528"/>
                <participants group_id="P2" count="525"/>
                <participants group_id="P3" count="527"/>
                <participants group_id="P4" count="522"/>
                <participants group_id="P5" count="522"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="448"/>
                <participants group_id="P3" count="455"/>
                <participants group_id="P4" count="462"/>
                <participants group_id="P5" count="466"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not stated above</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This patient set included all patients in the randomised set who were dispensed study medication and were documented to have taken any dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Olodaterol (5 μg)</title>
          <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium (2.5 μg)</title>
          <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium (5 μg)</title>
          <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B4">
          <title>Tio+Olo FDC (2.5/5 μg)</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B5">
          <title>Tio+Olo FDC (5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="528"/>
            <count group_id="B2" value="525"/>
            <count group_id="B3" value="527"/>
            <count group_id="B4" value="522"/>
            <count group_id="B5" value="522"/>
            <count group_id="B6" value="2624"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="8.0"/>
                    <measurement group_id="B2" value="64.2" spread="8.6"/>
                    <measurement group_id="B3" value="64.2" spread="8.5"/>
                    <measurement group_id="B4" value="64.1" spread="8.0"/>
                    <measurement group_id="B5" value="64.8" spread="8.2"/>
                    <measurement group_id="B6" value="64.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="133"/>
                    <measurement group_id="B5" value="138"/>
                    <measurement group_id="B6" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="386"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="383"/>
                    <measurement group_id="B4" value="389"/>
                    <measurement group_id="B5" value="384"/>
                    <measurement group_id="B6" value="1934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.</time_frame>
        <population>The Full analysis set (FAS) included all patients who were randomised, who were dispensed study medication, were documented to have taken any dose of study medication and who had a non-missing baseline and at least one non-missing post-baseline measurement before or at Week 24 for any of the primary and key secondary efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.</description>
          <population>The Full analysis set (FAS) included all patients who were randomised, who were dispensed study medication, were documented to have taken any dose of study medication and who had a non-missing baseline and at least one non-missing post-baseline measurement before or at Week 24 for any of the primary and key secondary efficacy endpoints.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" spread="0.008"/>
                    <measurement group_id="O2" value="0.148" spread="0.008"/>
                    <measurement group_id="O3" value="0.139" spread="0.008"/>
                    <measurement group_id="O4" value="0.241" spread="0.008"/>
                    <measurement group_id="O5" value="0.256" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.100</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.117</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.086</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.070</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2169</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5849</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1863</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4352</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.014</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response on Day 170.</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 170.</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.009"/>
                    <measurement group_id="O2" value="0.083" spread="0.008"/>
                    <measurement group_id="O3" value="0.065" spread="0.008"/>
                    <measurement group_id="O4" value="0.111" spread="0.008"/>
                    <measurement group_id="O5" value="0.136" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0174</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0407</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3326</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0151</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.053</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1421</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 169</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="954"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="954"/>
                <count group_id="O4" value="990"/>
                <count group_id="O5" value="979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.366" spread="0.396"/>
                    <measurement group_id="O2" value="37.792" spread="0.390"/>
                    <measurement group_id="O3" value="37.907" spread="0.393"/>
                    <measurement group_id="O4" value="37.335" spread="0.385"/>
                    <measurement group_id="O5" value="36.674" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.693</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.553</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.778</ci_lower_limit>
            <ci_upper_limit>-0.608</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0252</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.551</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.313</ci_lower_limit>
            <ci_upper_limit>-0.153</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0620</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.031</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.552</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.113</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4051</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.456</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.548</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.531</ci_lower_limit>
            <ci_upper_limit>0.618</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2988</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.571</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.550</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.649</ci_lower_limit>
            <ci_upper_limit>0.507</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2249</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.662</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.545</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.731</ci_lower_limit>
            <ci_upper_limit>0.407</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0418</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.549</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.195</ci_lower_limit>
            <ci_upper_limit>-0.042</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4097</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.460</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.557</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.552</ci_lower_limit>
            <ci_upper_limit>0.633</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg)
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3013</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.575</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.556</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.664</ci_lower_limit>
            <ci_upper_limit>0.515</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8355</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.554</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.970</ci_lower_limit>
            <ci_upper_limit>1.200</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 169</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.564" spread="0.096"/>
                    <measurement group_id="O2" value="1.690" spread="0.095"/>
                    <measurement group_id="O3" value="1.627" spread="0.096"/>
                    <measurement group_id="O4" value="1.980" spread="0.095"/>
                    <measurement group_id="O5" value="1.983" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.420</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.155</ci_lower_limit>
            <ci_upper_limit>0.684</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.356</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.619</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.416</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.681</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0307</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.290</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.554</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.352</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.089</ci_lower_limit>
            <ci_upper_limit>0.616</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9801</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.259</ci_lower_limit>
            <ci_upper_limit>0.266</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0289</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.294</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.557</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6382</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.202</ci_lower_limit>
            <ci_upper_limit>0.330</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3525</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.140</ci_lower_limit>
            <ci_upper_limit>0.391</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6457</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.327</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response on Day 1</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment.</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response on Day 1</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.205" spread="0.009"/>
                    <measurement group_id="O2" value="0.148" spread="0.009"/>
                    <measurement group_id="O3" value="0.157" spread="0.009"/>
                    <measurement group_id="O4" value="0.226" spread="0.009"/>
                    <measurement group_id="O5" value="0.237" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.081</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0746</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.054</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3549</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.072</ci_lower_limit>
            <ci_upper_limit>-0.025</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5018</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.016</ci_lower_limit>
            <ci_upper_limit>0.032</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response on Day 85</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85.</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response on Day 85</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.009"/>
                    <measurement group_id="O2" value="0.176" spread="0.009"/>
                    <measurement group_id="O3" value="0.162" spread="0.009"/>
                    <measurement group_id="O4" value="0.271" spread="0.009"/>
                    <measurement group_id="O5" value="0.289" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.104</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.150</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1569</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.041</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.089</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8834</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2129</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2702</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.010</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response on Day 365</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365.</time_frame>
        <population>FAS (on day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response on Day 365</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (on day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.009"/>
                    <measurement group_id="O2" value="0.116" spread="0.009"/>
                    <measurement group_id="O3" value="0.122" spread="0.009"/>
                    <measurement group_id="O4" value="0.214" spread="0.009"/>
                    <measurement group_id="O5" value="0.237" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.117</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.067</ci_lower_limit>
            <ci_upper_limit>0.117</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0717</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0344</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1126</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6009</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 15.</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
        <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 15.</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085" spread="0.009"/>
                    <measurement group_id="O2" value="0.101" spread="0.009"/>
                    <measurement group_id="O3" value="0.094" spread="0.009"/>
                    <measurement group_id="O4" value="0.132" spread="0.009"/>
                    <measurement group_id="O5" value="0.157" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0122</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.030</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0347</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4407</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1777</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5641</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 43</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43.</time_frame>
        <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 43</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" spread="0.009"/>
                    <measurement group_id="O2" value="0.097" spread="0.009"/>
                    <measurement group_id="O3" value="0.088" spread="0.009"/>
                    <measurement group_id="O4" value="0.120" spread="0.009"/>
                    <measurement group_id="O5" value="0.163" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0517</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.000</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6619</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.005</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2401</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4601</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.015</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 85</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 85.</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 85</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.009"/>
                    <measurement group_id="O2" value="0.077" spread="0.009"/>
                    <measurement group_id="O3" value="0.070" spread="0.009"/>
                    <measurement group_id="O4" value="0.128" spread="0.009"/>
                    <measurement group_id="O5" value="0.146" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1405</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3118</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.036</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1171</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5759</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 169</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on Day 169</time_frame>
        <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 169</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.009"/>
                    <measurement group_id="O2" value="0.047" spread="0.009"/>
                    <measurement group_id="O3" value="0.050" spread="0.009"/>
                    <measurement group_id="O4" value="0.094" spread="0.009"/>
                    <measurement group_id="O5" value="0.112" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.068</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1360</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1617</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.041</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2476</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8083</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.027</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 365</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 365</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.000" spread="0.009"/>
                    <measurement group_id="O2" value="0.028" spread="0.009"/>
                    <measurement group_id="O3" value="0.036" spread="0.009"/>
                    <measurement group_id="O4" value="0.075" spread="0.009"/>
                    <measurement group_id="O5" value="0.099" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.075</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.040</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0554</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0248</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.053</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5338</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.032</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 1</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment.</time_frame>
        <population>FAS (day 1). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 1</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 1). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.350" spread="0.017"/>
                    <measurement group_id="O2" value="0.277" spread="0.017"/>
                    <measurement group_id="O3" value="0.289" spread="0.017"/>
                    <measurement group_id="O4" value="0.400" spread="0.017"/>
                    <measurement group_id="O5" value="0.427" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0426</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2661</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0119</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.109</ci_lower_limit>
            <ci_upper_limit>-0.014</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.121</ci_lower_limit>
            <ci_upper_limit>-0.025</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6408</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 85</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85.</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 85</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.247" spread="0.017"/>
                    <measurement group_id="O2" value="0.318" spread="0.017"/>
                    <measurement group_id="O3" value="0.275" spread="0.017"/>
                    <measurement group_id="O4" value="0.432" spread="0.017"/>
                    <measurement group_id="O5" value="0.469" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.221</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.173</ci_lower_limit>
            <ci_upper_limit>0.270</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.193</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.145</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.114</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1355</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.151</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2562</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0815</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.091</ci_lower_limit>
            <ci_upper_limit>0.005</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 169</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.</time_frame>
        <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 169</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.212" spread="0.017"/>
                    <measurement group_id="O2" value="0.279" spread="0.017"/>
                    <measurement group_id="O3" value="0.254" spread="0.017"/>
                    <measurement group_id="O4" value="0.386" spread="0.017"/>
                    <measurement group_id="O5" value="0.407" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.195</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.149</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.128</ci_lower_limit>
            <ci_upper_limit>0.221</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.107</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.086</ci_lower_limit>
            <ci_upper_limit>0.178</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3727</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.175</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0744</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2945</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.071</ci_lower_limit>
            <ci_upper_limit>0.022</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 365</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365.</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 365</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="521"/>
                <count group_id="O5" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" spread="0.018"/>
                    <measurement group_id="O2" value="0.241" spread="0.018"/>
                    <measurement group_id="O3" value="0.221" spread="0.018"/>
                    <measurement group_id="O4" value="0.364" spread="0.018"/>
                    <measurement group_id="O5" value="0.377" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.205</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.155</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.142</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6103</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0559</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.049</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4368</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.020</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.070</ci_lower_limit>
            <ci_upper_limit>0.030</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 15.</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
        <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 15.</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.149" spread="0.018"/>
                    <measurement group_id="O2" value="0.222" spread="0.018"/>
                    <measurement group_id="O3" value="0.220" spread="0.018"/>
                    <measurement group_id="O4" value="0.270" spread="0.018"/>
                    <measurement group_id="O5" value="0.296" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0545</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0456</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2949</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.074</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9369</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 43.</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43</time_frame>
        <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 43.</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" spread="0.018"/>
                    <measurement group_id="O2" value="0.206" spread="0.018"/>
                    <measurement group_id="O3" value="0.213" spread="0.018"/>
                    <measurement group_id="O4" value="0.254" spread="0.018"/>
                    <measurement group_id="O5" value="0.318" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.054</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0585</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1042</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.161</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0120</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0250</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7889</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 85.</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 85.</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.077" spread="0.018"/>
                    <measurement group_id="O2" value="0.168" spread="0.018"/>
                    <measurement group_id="O3" value="0.144" spread="0.018"/>
                    <measurement group_id="O4" value="0.230" spread="0.018"/>
                    <measurement group_id="O5" value="0.265" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.187</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.237</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.202</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0134</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.111</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1670</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0085</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.090</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3332</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.074</ci_lower_limit>
            <ci_upper_limit>0.025</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 170.</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 170.</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" spread="0.017"/>
                    <measurement group_id="O2" value="0.184" spread="0.017"/>
                    <measurement group_id="O3" value="0.169" spread="0.017"/>
                    <measurement group_id="O4" value="0.225" spread="0.017"/>
                    <measurement group_id="O5" value="0.246" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0926</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3802</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0105</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5554</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.062</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 365.</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on Day 365.</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 365.</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
                <count group_id="O3" value="520"/>
                <count group_id="O4" value="518"/>
                <count group_id="O5" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.018"/>
                    <measurement group_id="O2" value="0.114" spread="0.018"/>
                    <measurement group_id="O3" value="0.108" spread="0.018"/>
                    <measurement group_id="O4" value="0.155" spread="0.018"/>
                    <measurement group_id="O5" value="0.191" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1112</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0632</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1615</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.044</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7925</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.057</ci_lower_limit>
            <ci_upper_limit>0.044</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-12h) Response in the Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169.</time_frame>
        <population>12 hr PFT set: All patients who have given Informed Consent for the 12-hour PFT testing and had any spirometry measurement after 3-hour and before or at 12-hours post-dose on Days 169 and 170.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-12h) Response in the Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12 hr PFT set: All patients who have given Informed Consent for the 12-hour PFT testing and had any spirometry measurement after 3-hour and before or at 12-hours post-dose on Days 169 and 170.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.131" spread="0.015"/>
                    <measurement group_id="O2" value="0.109" spread="0.016"/>
                    <measurement group_id="O3" value="0.127" spread="0.017"/>
                    <measurement group_id="O4" value="0.202" spread="0.016"/>
                    <measurement group_id="O5" value="0.250" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0384</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8428</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3048</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.020</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4311</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-24h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169.</time_frame>
        <population>12−hr PFT set</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-24h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12−hr PFT set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.108" spread="0.014"/>
                    <measurement group_id="O2" value="0.083" spread="0.015"/>
                    <measurement group_id="O3" value="0.100" spread="0.016"/>
                    <measurement group_id="O4" value="0.159" spread="0.015"/>
                    <measurement group_id="O5" value="0.206" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.106</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0136</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0277</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7116</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2332</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.016</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4374</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-12h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169.</time_frame>
        <population>12−hr PFT set</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-12h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12−hr PFT set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.227" spread="0.029"/>
                    <measurement group_id="O2" value="0.180" spread="0.030"/>
                    <measurement group_id="O3" value="0.248" spread="0.032"/>
                    <measurement group_id="O4" value="0.356" spread="0.030"/>
                    <measurement group_id="O5" value="0.388" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.244</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0141</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4581</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.208</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.293</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6335</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.064</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2530</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.129</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1188</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-24h) Response in Sub-set of Patients With 24-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169.</time_frame>
        <population>12−hr PFT set</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-24h) Response in Sub-set of Patients With 24-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12−hr PFT set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" spread="0.028"/>
                    <measurement group_id="O2" value="0.141" spread="0.028"/>
                    <measurement group_id="O3" value="0.203" spread="0.030"/>
                    <measurement group_id="O4" value="0.297" spread="0.029"/>
                    <measurement group_id="O5" value="0.329" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0085</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0255</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4393</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7784</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1965</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.129</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1315</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="954"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="955"/>
                <count group_id="O4" value="990"/>
                <count group_id="O5" value="979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.832" spread="0.398"/>
                    <measurement group_id="O2" value="37.821" spread="0.397"/>
                    <measurement group_id="O3" value="37.822" spread="0.399"/>
                    <measurement group_id="O4" value="37.304" spread="0.392"/>
                    <measurement group_id="O5" value="36.691" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.560</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.239</ci_lower_limit>
            <ci_upper_limit>-1.043</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0435</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.560</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.230</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.528</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.559</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.623</ci_lower_limit>
            <ci_upper_limit>-0.432</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3545</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.517</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.558</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.611</ci_lower_limit>
            <ci_upper_limit>0.577</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3542</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.518</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.559</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.614</ci_lower_limit>
            <ci_upper_limit>0.578</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2697</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.613</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.556</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.702</ci_lower_limit>
            <ci_upper_limit>0.476</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0434</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.559</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.227</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0732</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.563</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.114</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0724</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.563</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.114</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9983</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.563</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.102</ci_lower_limit>
            <ci_upper_limit>1.104</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="954"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="955"/>
                <count group_id="O4" value="990"/>
                <count group_id="O5" value="979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.989" spread="0.414"/>
                    <measurement group_id="O2" value="37.609" spread="0.409"/>
                    <measurement group_id="O3" value="37.581" spread="0.411"/>
                    <measurement group_id="O4" value="37.553" spread="0.403"/>
                    <measurement group_id="O5" value="37.138" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.852</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.578</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.985</ci_lower_limit>
            <ci_upper_limit>-0.718</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4413</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.444</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.573</ci_lower_limit>
            <ci_upper_limit>0.686</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0129</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.437</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.578</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.569</ci_lower_limit>
            <ci_upper_limit>-0.304</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9222</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.574</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.182</ci_lower_limit>
            <ci_upper_limit>1.070</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9602</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.157</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4669</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.415</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.570</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.533</ci_lower_limit>
            <ci_upper_limit>0.703</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4126</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.471</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.575</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.598</ci_lower_limit>
            <ci_upper_limit>0.656</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0158</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.408</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.583</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.551</ci_lower_limit>
            <ci_upper_limit>-0.265</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0177</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.381</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.582</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.521</ci_lower_limit>
            <ci_upper_limit>-0.240</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9624</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.580</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.164</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 43 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 43</time_frame>
        <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 43 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.453" spread="0.096"/>
                    <measurement group_id="O2" value="1.430" spread="0.097"/>
                    <measurement group_id="O3" value="1.408" spread="0.097"/>
                    <measurement group_id="O4" value="1.876" spread="0.096"/>
                    <measurement group_id="O5" value="2.048" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.595</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.329</ci_lower_limit>
            <ci_upper_limit>0.862</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.640</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.373</ci_lower_limit>
            <ci_upper_limit>0.907</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.423</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.690</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.446</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>0.712</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.468</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.201</ci_lower_limit>
            <ci_upper_limit>0.735</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2045</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.094</ci_lower_limit>
            <ci_upper_limit>0.438</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.618</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.351</ci_lower_limit>
            <ci_upper_limit>0.885</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7432</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.313</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8687</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.290</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8709</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.290</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 85 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 85</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 85 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.506" spread="0.097"/>
                    <measurement group_id="O2" value="1.698" spread="0.097"/>
                    <measurement group_id="O3" value="1.702" spread="0.097"/>
                    <measurement group_id="O4" value="1.925" spread="0.096"/>
                    <measurement group_id="O5" value="2.136" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.630</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.362</ci_lower_limit>
            <ci_upper_limit>0.898</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.434</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.703</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.419</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.687</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0966</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.227</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.495</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1029</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.223</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.492</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1220</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.056</ci_lower_limit>
            <ci_upper_limit>0.478</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.438</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.707</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1542</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.074</ci_lower_limit>
            <ci_upper_limit>0.465</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1626</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.077</ci_lower_limit>
            <ci_upper_limit>0.461</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9765</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.138</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.265</ci_lower_limit>
            <ci_upper_limit>0.274</ci_upper_limit>
            <estimate_desc>Tiotropium (5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
        <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 365 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)</title>
          <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 365 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.411" spread="0.101"/>
                    <measurement group_id="O2" value="1.450" spread="0.100"/>
                    <measurement group_id="O3" value="1.736" spread="0.101"/>
                    <measurement group_id="O4" value="1.782" spread="0.099"/>
                    <measurement group_id="O5" value="2.058" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.647</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.370</ci_lower_limit>
            <ci_upper_limit>0.925</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0226</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.322</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.600</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 μg) versus Tiotropium (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0089</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.371</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.649</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Olodaterol (5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.332</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.609</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7441</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.231</ci_lower_limit>
            <ci_upper_limit>0.324</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (2.5/5 μg) versus Tiotropium (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0492</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.276</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.551</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tio+Olo FDC (2.5/5 μg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.608</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.332</ci_lower_limit>
            <ci_upper_limit>0.884</ci_upper_limit>
            <estimate_desc>Tio+Olo FDC (5/5 µg) versus Tiotropium (2.5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0230</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.325</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.605</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg)
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7855</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.240</ci_lower_limit>
            <ci_upper_limit>0.317</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0442</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.286</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.564</ci_upper_limit>
            <estimate_desc>Tiotropium (2.5 µg) versus Olodaterol (5 µg).
Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse events with an onset after the first dose of study medication up to a period of 21 days after the last dose of study medication were assigned to the treatment period for evaluation (Up to 447 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olodaterol (5 μg)</title>
          <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium (2.5 μg)</title>
          <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium (5 μg)</title>
          <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E4">
          <title>Tio+Olo FDC (2.5/5 μg)</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E5">
          <title>Tio+Olo FDC (5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pancreatic duct dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Electrocution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Fascial hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Enchondroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Critical illness polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="210" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="211" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="193" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="525"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="527"/>
                <counts group_id="E4" subjects_affected="133" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="134" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

